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Abstract
Aims/hypothesis Current drug labels for thiazolidinediones
(TZDs) warn of increased fractures, predominantly for distal
fractures in women. We examined whether exposure to
TZDs affects hip fracture in women and men and compared
the risk to that found with other drugs used in diabetes.
Methods Using a nationwide database of prescriptions, hos-
pital admissions and deaths in those with type 2 diabetes in
Scotland we calculated TZD exposure among 206,672 indi-
viduals. Discrete-time failure analysis was used to model the
effect of cumulative drug exposure on hip fracture during
1999–2008.
Results There were 176 hip fractures among 37,479 ex-
posed individuals. Hip fracture risk increased with cumula-
tive exposure to TZD: OR per year of exposure 1.18 (95%
CI 1.09, 1.28; p03×10−5), adjusted for age, sex and calen-
dar month. Hip fracture increased with cumulative exposure
in both men (OR 1.20; 95% CI 1.03, 1.41) and women (OR
1.18; 95% CI 1.07, 1.29) and risks were similar for piogli-
tazone (OR 1.18) and rosiglitazone (OR 1.16). The
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association was similar when adjusted for exposure to other
drugs for diabetes and for other potential confounders.
There was no association of hip fracture with cumulative
exposure to sulfonylureas, metformin or insulin in this analy-
sis. The 90-day mortality associated with hip fractures was
similar in ever-users of TZD (15%) and in never-users (13%).
Conclusions/interpretation Hip fracture is a severe adverse
effect with TZDs, affecting both sexes; labels should be
changed to warn of this. The excess mortality is at least as
much as expected from the reported association of pioglita-
zone with bladder cancer.
Keywords Fractures . Hip fracture . Pharmacoepidemiology .
Thiazolidinedione . Type 2 diabetes
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Introduction
Based on its association with cardiovascular disease, the
thiazolidinedione (TZD) rosiglitazone has been withdrawn
in Europe and is on restricted licence in the USA. Last year
the prescribing information for pioglitazone was updated by
the European Medicines Agency (EMA) and other regula-
tory agencies because of reports of a risk ratio for bladder
cancer ranging from 1.12 to 1.33 after 2 years' exposure.
Pioglitazone was stated to be a valid treatment option for
certain patients with type 2 diabetes, specifically when
metformin has not been suitable or has failed to work
adequately [1–3].
However, another important adverse effect of TZD ther-
apy is bone fracture. That TZDs can cause fracture was first
suggested by the ADOPT clinical trial, in which rosiglita-
zone treatment increased distal fracture risk in women only
[4]. Since then other trials [5–7] and observational studies
[8–13] have reported on fracture risk with TZD. These
studies are generally consistent in finding an increased risk
in older women for distal fracture but they are inconsistent
with respect to effects in men and effects on hip fractures.
Establishing whether TZDs cause hip fracture is important
given the high rates of mortality associated with hip as
compared with distal fractures [14, 15]. Few studies have
had adequate power to examine these effects and none have
adjusted for prior exposure to all other main classes of drugs
for diabetes. Meanwhile, the drug labels continue to empha-
sise that TZD-associated fracture risk is predominantly for
distal fractures in women. In this analysis we have used data
from a Scotland-wide diabetes register to examine whether
cumulative exposure to TZDs also affects hip fracture rates
in women and in men, whether exposure to other glucose-
lowering drugs explains any associated risks and to compare
the risks associated with rosiglitazone and pioglitazone.
Methods
Ethical approval Approval was obtained from the Scot-
land A Research Ethics Committee, the Caldicott (data
privacy) Guardians for the 14 Scottish Health Boards
and the NHS Information Services Division Privacy
Advisory Committee.
Data sources In Scotland patients with type 2 diabetes are
registered on a nationwide clinical record system that also
includes issued prescriptions and other clinical data from
primary care and diabetes clinics–the Scottish Care Infor-
mation–Diabetes Collaboration (SCI-DC) database [16].
SCI-DC data are linked anonymously to hospital admissions
data (Scottish Morbidity Record SMR-01), held by the
Information Services Division of the National Health Ser-
vice (NHS), and death data held by the General Register
Office for Scotland, using the healthcare number with prob-
abilistic linkage (mal-linkage rate <3%) [17]. From the
linked data, we extracted data on hip fractures. We used
the standard ICD-10 codes (www.who.int/classifications/
icd/en/) used by the Information Services Division of the
NHS and we excluded admissions containing codes for traffic
accidents and other severe external causes that might be
expected to cause fractures even in individuals not susceptible
to fracture (see Appendix for ICD-10 codes used).
Cohort under study and dates of entry and exit from follow-
up We extracted anonymised data on all drug prescriptions
and potential confounders from SCI-DC for all patients with
type 2 diabetes ever registered on SCI-DC who were under
observation for prescribing records in SCI-DC at some time
during 1999–2008 (n0225,821). Using the prescription data
we defined all stretches of exposure to TZD, metformin,
insulin and sulfonylurea for each patient. We defined the
period of follow-up for the analysis as being from 1 January
1999 (the year in which TZD prescribing started in Scot-
land) to 2008 (the most recent data available to us); thus all
TZD users included in the analysis are incident users. To
model the univariate effects of TZD, we selected all indi-
viduals who were evaluable for cumulative exposure to
TZDs (i.e. anyone with more than 1 year of diabetes in
which drug exposure was unknown since introduction of
TZDs in 1999 was excluded) giving a total cohort of
206,672 individuals. To model the joint effects of all main
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classes of glucose-lowering drugs (sulfonylureas, metfor-
min, insulin, TZD), the analysis was restricted to a subset
of 173,113 individuals who first came under observation for
drug exposures no more than 1 year after diagnosis of
diabetes (i.e. who were evaluable for cumulative exposure
to all classes of drugs for diabetes). For each individual the
date of entry into the analysis was the latest of three dates:
first date under observation for drug prescribing, 1 January
1999 or date of diabetes diagnosis. The exit date was the
earliest of four dates: date of first hip fracture, date of death,
last date under observation or 31 December 2008.
Data preparation for modelling and calculation of exposure
The period of follow-up (1 January 1999 to 31 December
2008) was divided into discrete intervals of 28 days and
occurrence of hip fracture in any interval was scored as a
binary variable. A data matrix was generated with one row
for each individual under observation in each 28-day inter-
val, and columns specifying event status (coded as binary),
fixed covariates (sex, prior fracture at any site) and time-
varying covariates (age, calendar month, ever exposed to
drug of interest by the start of the interval and cumulative
exposure to each drug). For each drug class, cumulative
exposure at the start of each interval was calculated as a
sum over all earlier intervals in which a drug prescription
was current. The exposure duration was calculated from the
first and last dates of a run of repeat prescriptions at a given
dose plus the duration of the last prescription in that run.
Gaps between runs of repeat prescriptions did not accumu-
late exposure. Following drug cessation the cumulative days
of exposure at cessation was then carried forward in subse-
quent time intervals. Gaps in being under observation for
prescribing records (possibly representing temporary ab-
sence from Scotland) were ignored when defining the first
and last dates under observation, as such gaps represented
less than 5% of all person-years between first and last
prescription records.
Statistical methods The effects of cumulative exposure were
evaluated in a discrete-time survival model [18, 19]; this is
set up as a logistic regression model in which each individ-
ual contributes one observation for each 28-day interval
between their entry and exit dates. We must use discrete
time intervals in any case to model time-varying covariates
such as cumulative exposure, and with short intervals of
equal length very little information is lost by encoding the
failures within each interval as binary (for logistic regres-
sion) rather than as times to failure within each interval (for
Poisson regression). The model included age, sex, calendar
month, ever-exposure to one or more drugs under study and
cumulative exposure to the same drugs. This model was
then run for each sex separately and with separate terms
for pioglitazone and rosiglitazone. To evaluate the effect of
dose we compared the deviance of the basic model in which
the cumulative exposure was calculated as years of exposure
(ignoring dose) to a model in which the cumulative expo-
sure was calculated as the sum of daily doses. We evaluated
the effects of other diabetes drugs and covariates by includ-
ing terms for ever-exposure and time-dependent cumulative
exposure to sulfonylureas, metformin and insulin, time-
dependent terms for time since diagnosis of diabetes, and
for baseline postmenopausal oestrogen therapy, prior car-
diovascular disease, prior fracture at any site, and exposure
to thyroid drugs, loop diuretics, steroids, tricyclic antide-
pressants and bisphosphonates. These potential confounders
were chosen based on the QFRACTURE fracture prediction
model [20], data availability and prior information about
drug effects on bone metabolism [21]. Smoking status be-
fore entry was recorded for just 61% of individuals under
study and BMI and HbA1c levels before entry were avail-
able for less than one-quarter of individuals.
Evaluation of drug effect Comparisons of fracture risk be-
tween ever-users and never-users of a drug are likely to be
confounded by ‘frailty’, in that those prescribed and those
not prescribed the drug may differ in their prior susceptibil-
ity to fracture. Such ‘allocation bias’ or ‘confounding by
indication’ cannot reliably be dealt with by simple adjust-
ment for measured covariates such as past medical history.
One way to be certain that an estimate of a drug's causal
effect cannot be due to such between-person confounding is
to model the data with two terms in the model: one a time-
updated term for ever-exposure up to that point in time and
one for time-updated cumulative exposure. The ever-
exposed term contrasts the rate in unexposed person time-
periods with the predicted rate in person time-periods when
exposure has just started. It is the sum of any stepwise
(immediate) effect of drug exposure on fracture and the
confounding effect of time-invariant frailty (i.e. allocation
bias). It can be shown algebraically that with the ever-use
term in the model the likelihood of the cumulative effect
term does not depend on the events in the unexposed and
therefore cannot be affected by allocation bias. Thus we
focus the inference of causality on the cumulative term. If
the drug does in fact cause an immediate increase in fracture
risk, then our conclusions based only on the cumulative
term are conservative.
Results
Comparison of exposed and unexposed individuals Of the
206,672 individuals whose cumulative TZD exposure could
be evaluated, 37,479 had accumulated some exposure to
TZDs by the end of follow-up. Table 1 shows comparison
of characteristics at entry to the cohort between those never-
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users and those eventual users of TZDs during the period of
follow-up, with p values, other than for the age comparison,
based on adjustment for age. Ever-users of TZD were sig-
nificantly younger than never-users. Adjusted for age, in
ever-users vs never-users of TZDs the proportion with
prior admission coded with cardiovascular disease was
lower, the proportion who had used bisphosphonates
was lower and the proportion of women who had used
postmenopausal oestrogens was higher, even after
adjusting for the difference in age at entry. Although
the crude proportion of females among the TZD users
was similar to never-users, after adjustment for the age
difference in users there was a higher proportion of
females among TZD users than would be expected.
Although crude smoking rates and thyroid drug usage
rates are the same in the two groups, adjusted for the
younger age of users, smoking is less common and
thyroid drug use more common than would be expected
in TZD users compared with never-users.
Effects of cumulative exposure There were 2,433 first hip
fracture events: 98 in current users of a TZD at the time of
fracture, 78 in ex-users and 2,258 in never-users. Of the 176
hip fractures in users, 44 were in men and 132 in women.
Figures 1 and 2 show the rates of hip fracture admission in
women and men by cumulative exposure to TZD standardised
(within 10-year age bands) to the age distributions (over all
person-years) of all women and all men under study, respec-
tively. In both women andmen the fracture rate in the first year
of exposure is lower than the overall fracture rate in the never-
exposed periods, consistent with the comparisons in Table 1,
which suggest that those eventual users of TZDs are likely to
be in better health (and thus presumably at less prior risk of
fracture) than those never exposed to TZDs. The plots show
that fracture rate rises with increasing exposure; while the data
fit a linear model and we use this linear term to describe the
effect per cumulative year of exposure subsequently, the
graphs also suggest a lag before fracture risk starts to increase,
and a flattening of the curve after 4 years of exposure.
Consistent with this a post hoc comparison, comparing rates
with 2–4 years and >4 years exposure with 1 day–2 years
exposure, gave estimates of OR 1.87 (95% CI 1.35, 2.61) and
1.94 (95% CI 1.28, 2.94), respectively, overall, with ORs of
1.72 (95% CI 1.17, 2.52) and 1.85 (95% CI 1.14, 3.00) in
women and ORs of 2.44 (95% CI 1.27, 4.7) and 2.28 (95% CI
0.99, 5.25) in men for these categories of exposure.
The terms for ever-exposure and cumulative exposure in
the discrete-time failure model can be given a visual inter-
pretation in this plot, which superimposes the regression line
for the linear effect of cumulative exposure (x) (see Fig. 1
Table 1 Comparison of characteristics at time of entry to the study between those never-users and those eventual users of TZDs (n0206,672)
Characteristic Never-users of TZD
(n0169,193)
Ever-TZD users
(n037,479)
p value for age-adjusted
differencea
Age (years), median (interquartile range) 65.2 (57.5–73.3) 58.3 (57.5–65.5) <0.001
No. of years since diagnosis of diabetes, median
(interquartile range)
0 (0–2.25) 0.1 (0–4.0) <0.001
Female, % (no.) 47 (78,977) 46 (17,374) <0.001
Current/past use of glucose-lowering drugs at entry to cohort, % (no.)
TZD 0 by definition 0.2 (65)
Metformin 10 (16,923) 17 (6,546) <0.001
Sulfonylureas 14 (24,303) 21 (7,910) <0.001
Insulin 4 (6,014) 1 (306) <0.001
Prior admission for fracture at any site, % (no.) 5 (8,706) 4 (1,612) <0.001
Prior admission for cardiovascular disease, % (no.) 17 (28,837) 12 (4,477) <0.001
Current/past use of other drugs, % (no.)
Steroids 8 (13,983) 8 (2,978) 0.6
Thyroid drugs 4 (7,186) 4 (1,468) <0.001b
Tricyclic antidepressants 7 (12,077) 7 (2,565) 0.18
Postmenopausal oestrogen (women only) 8 (5,995/78,977) 12 (2,113/17,374) <0.001
Bisphosphonates 1 (1,146) 0.3% (128) 0.005
Loop diuretics 14 (23,524) 10 (3,824) 0.33
Current smoking 30 (31,163/103,271) 30 (7,067/23,735) <0.001b
ap values are for the age-adjusted difference other than for age itself
bAlthough the crude rates for thyroid drug use and smoking are the same, the smoking rate in ever-users of TZDs is lower and use of thyroid drugs
is higher than expected given their younger age (i.e. adjusted for age, smoking is significantly lower and thyroid drug use is significantly higher)
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legend). Since an immediate stepwise effect of TZDs on hip
fracture is unlikely, the difference in height between the
regression line at x00 and the observed data point at x00
suggests that those who become exposed have a lower prior
fracture risk than those never exposed.
The OR for hip fracture with each cumulative year of
TZD exposure was 1.18 (95% CI 1.09, 1.28; p03×10−5) in
both sexes combined, adjusted for age, sex, calendar month
and ever-use of TZDs. The effect of cumulative exposure to
TZDs on hip fracture did not differ between men (OR 1.20
per year exposure, 95% CI 1.03, 1.41, based on 44 events in
exposed men) and women (OR 1.18, 95% CI 1.07, 1.29,
based on 132 events in exposed women). In a joint analysis
with cumulative and ever-use terms for both TZDs, the
effect per year of cumulative exposure did not differ be-
tween pioglitazone (OR 1.18; 95% CI 1.00, 1.40) and rosi-
glitazone (OR 1.16; 95% CI 1.06, 1.26). In comparison with
the model in which cumulative exposure was coded as years
of exposure, the deviance of the model in which cumulative
exposure was coded as total cumulative dose (standardised
as described in the Methods section) was three units higher,
indicating that the model fit was better for exposure coded
as cumulative years than cumulative milligram dose. In an
analysis with follow-up censored on cessation of TZD the
effect of cumulative exposure was slightly greater, consistent
with a dropping off of effect on cessation (OR 1.33, 95% 1.10,
1.61, p00.003). Using a Cox regression rather than discrete
time model gave the same estimate of effect for cumulative
exposure as the main model (OR 1.18, p03×10−5).
Over the entire period that individuals were under obser-
vation, the 90-day case fatality for hip fracture was similar at
15% in ever-users of TZDs and 13% in never-users.
Multivariate analysis including other drugs for diabetes
Table 2 summarises the results of models of hip fracture
risk in the subset of 173,113 individuals who were evaluable
for cumulative exposure to all four glucose-lowering drug
classes. In model 1 adjusted for sex, age, calendar month
and ever-exposure, the OR per year of cumulative exposure
to TZDs was 1.21 (95% CI 1.09, 1.35). With additional
adjustment for years since diagnosis, prior cardiovascular
disease, prior admission for fracture, past exposure to drugs
likely to affect fracture risk, and cumulative and ever-use
terms for sulfonylureas, metformin and insulin (model 2),
the OR for hip fracture per year of cumulative exposure to
TZDs was 1.19 (95% CI 1.07, 1.32). Hip fracture was
positively associated with years since diagnosis of diabetes,
prior admission for fracture, use of bisphosphonates and use
of tricyclic antidepressants, and inversely associated with
use of postmenopausal oestrogens in women. Further ad-
justment for statins, benzodiazepines, opiates, proton-pump
inhibitors, thiazides, beta blockers, ACE inhibitors and an-
giotensin II (AII) receptor antagonists did not alter the con-
clusions (OR 1.15, p00.004). In the 61% in whom smoking
status data was available, on adjustment for smoking the
effect remained significant (OR 1.12, p00.02).
Fig. 1 Age-standardised rates of hip fracture by cumulative exposure
to TZD in women. The error bars indicate the 95% CI for the rates. The
x axis shows cumulative years of exposure; the data point at x00 is for
all unexposed person time-periods, and the other data points are for
exposure categories 0<x≤1, 1<x≤2, 2<x≤3, 3<x≤4 and x>4 years.
The dotted regression line shows the linear effect of cumulative expo-
sure (x) calculated by weighted least squares from the ever-exposed
data points as an approximation to the modelling approach described in
the Methods. Whereas the data point at x00 is the log fracture rate
observed for all unexposed person time-periods, the point on the dotted
regression line where x00 is the estimate from the model of the log
fracture rate at the point of starting exposure in those exposed. Thus the
difference in height between these two points gives the magnitude of
the ever-exposed term and is the sum of any immediate stepwise effect
of the drug and any difference in prior risk of fracture in ever vs never
exposed. Since an immediate stepwise effect of TZD on hip fracture is
unlikely the difference in height suggests that those who become
exposed have a lower prior fracture risk than the never exposed
Fig. 2 Age-standardised rates of hip fractures by cumulative exposure
to TZD in men. The error bars indicate the 95% CI for the rates. See
legend to Fig. 1 for interpretation of this figure
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The model shows that there is no significant associ-
ation of cumulative exposure to other glucose-lowering
drugs with hip fracture. The ever-use terms for other
drugs are consistent with allocation to sulfonylureas and
insulin being associated with greater fracture suscepti-
bility and allocation to metformin being associated with
lower fracture susceptibility.
Discussion
In this nationwide cohort TZD treatment was associated
with an 18% relative increase in hip fracture rates for every
cumulative year of TZD exposure, in both men and women.
The risk was similar for rosiglitazone and pioglitazone.
There was no evidence that cumulative exposure to insulin,
sulfonylurea or metformin were independently associated
with hip fracture.
Our data add to growing evidence from observational
studies and trials on TZD-associated fracture and serve to
clarify several remaining questions about this risk [4–13,
22]. Our study was sufficiently large to be able to demonstrate
effects in men and on hip fracture, for both of which smaller
studies in the literature have reported inconsistent findings.
Our study included more male TZD users (20,105 vs 3,064)
than the extensive meta-analysis of randomised trial data
carried out by Loke et al [13] and this is likely to explain
why we have detected effects in men not apparent in trials. A
previous cohort study found that total fractures were increased
in men but included few patients over 65 years old and so was
underpowered for detecting effects on hip fracture [8]. One
self-controlled case series study reported an increase in hip
fracture in women and total fracture in men though the effect
on hip fracture in men did not reach statistical significance
[22]. The self-controlled case series design minimises be-
tween subject allocation bias but the method as originally
Table 2 Discrete-time failure
models for first hip fracture in
cohort restricted to those
first observed within 1 year
of diagnosis of diabetes
(n0173,133)
Model 1: association of hip
fracture with cumulative years
exposure to TZD with adjust-
ment for sex and time-varying
covariates (age, calendar month,
ever-use of TZD). See Methods
for the interpretation of the
ever-use term
Model 2: Model 1 plus
adjustment for additional baseline
covariates (prior cardiovascular
disease, prior fracture, past use
of fracture-associated drugs)
and additional time-varying
covariates (years since diagnosis,
ever-use and cumulative use
of three other classes of glucose-
lowering drugs [sulfonylureas,
metformin, insulin])
See Methods for the
interpretation of the ever-use
term
Model OR CI, lower CI, upper p value
Model 1
Women vs men 2.44 2.17 2.74 <0.001
Age years 1.12 1.11 1.12 <0.001
Calendar years 1.03 1.01 1.05 0.004
Ever TZD 0.69 0.50 0.95 0.024
Cumulative TZD (effect per year) 1.21 1.09 1.35 <0.001
Model 2
Sex 2.39 2.12 2.70 <0.001
Age years 1.11 1.10 1.12 <0.001
Calendar years 1.04 1.02 1.06 <0.001
Years from diagnosis 1.08 1.05 1.11 <0.001
Prior fracture 2.08 1.77 2.43 <0.001
Prior cardiovascular disease 1.02 0.90 1.17 0.710
Past drug exposure
Steroid 0.95 0.80 1.12 0.55
Post-menopausal oestrogen 0.60 0.42 0.86 0.005
Tricyclic 1.47 1.25 1.72 <0.001
Thyroid drugs 0.95 0.78 1.15 0.59
Bisphosphonates 1.69 1.22 2.33 0.001
Loop diuretics 1.07 0.95 1.21 0.25
Diabetes drug exposure
Ever sulfonylurea 1.31 1.14 1.52 <0.001
Ever metformin 0.75 0.64 0.87 <0.001
Ever insulin 1.13 0.83 1.55 0.43
Ever TZD 0.61 0.44 0.85 0.003
Cumulative sulfonylurea years 1.01 0.99 1.04 0.440
Cumulative metformin years 1.02 1.00 1.05 0.095
Cumulative insulin years 1.03 0.96 1.11 0.35
Cumulative TZD years 1.19 1.07 1.32 0.001
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conceived assumes that the observation time for each case is
independent of the event time. Where the event has a high
mortality rate (as we have shown is the case with hip fracture)
this assumption is violated. Recent modifications to the meth-
od render it less sensitive to assumption but the modified
method remains sensitive to the assumption that exposure is
not event dependent–in the case of hip fracture and TZDs this
assumption cannot be made; TZD exposure is less likely once
fracture has occurred [23]. One case–control study with
18,000 fracture cases found effects on total and hip fracture
in women and no overall or hip effect in men but the levels of
TZD exposure in men were low (only 1,971 exposed men
were included) [24]. A recent report also found evidence of a
cumulative effect of TZDs on total fracture but not hip fracture
[25].
The data reported here also clarify that the fracture risks
cannot be avoided by using pioglitazone instead of the now-
restricted rosiglitazone. Three previous studies reported sim-
ilar hazard rates for both drugs [8], with one reporting larger
effects for pioglitazone [9] and one larger effects for rosi-
glitazone [26]. However, none of them adjusted for expo-
sure to the other TZD drug in their analysis as we did, so
carry-over effects could not be excluded. In the previous
study that involved an analysis for pioglitazone restricted to
those with no prior exposure to rosiglitazone, pioglitazone
was clearly associated with an increased risk [22]. Another
strength of our study is that we have also simultaneously
modelled the effects of cumulative exposure to TZDs, met-
formin, sulfonylureas and insulin, thus ensuring that the
association of fractures with TZDs cannot be attributed to
these other diabetes drugs. This is important because previ-
ous observational studies were unable to adjust for time-
varying exposure to all these drugs. Thus our data add to
existing data and provide strong evidence for causality of
the TZD's effect because of its magnitude and because of no
similar cumulative effect with other glucose-lowering drug
classes being evident.
Inference of adverse drug effects from observational data
presents methodological challenges, especially confounding
of the association of drug allocation with outcome by sus-
ceptibility. In Scotland, TZD recipients have a more favour-
able profile of risk factors for fracture (less use of thyroid
drugs, less apparent need for bisphosphonates, more use of
postmenopausal oestrogens, fewer previous admissions for
fracture) and appear to be in better health (fewer previous
admissions for cardiovascular disease) than non-users at the
same age. Also the estimates of the ‘ever’ term for TZD
exposure from the model are consistent with those being
allocated TZD having a lower fracture risk than non-users at
the outset of TZD exposure (as they are for metformin too).
Thus a simple comparison of ever vs never-users of TZDs
would be confounded by indication (i.e. subject to allocation
bias). For this reason we have based inference only on the
cumulative effect of TZD on risk since this is not affected by
confounders that are not time-varying. This assumes that
drug exposure has no stepwise effect on fracture risk but, as
bone mass changes only slowly, this is a reasonable assump-
tion unless the drug causes falls, which is unlikely since
TZDs do not cause acute hypoglycaemia. The post hoc
analysis categorising cumulative exposure into 1 day to
2 years, 2–4 years and ≥4 years suggests that some threshold
of cumulative exposure may be needed before effects are
apparent. The greater effect when follow-up is censored at
cessation is consistent with a dropping off of the effect when
the drug is stopped, though we have not modelled this explic-
itly. Thus the effects at a given level of ongoing exposure may
be higher than we estimate. Of course while we have shown a
dose–response effect that seems specific to TZDs these are not
the only criteria for causality. It remains possible that long-
term glitazone users may differ from short-term users in their
base risk of hip fractures. Relevant in assessing causality too is
that there is a biological rationale; while there are several
possible mechanisms through which TZDs might lead to
fracture (e.g. by increasing falls) there is considerable evi-
dence that peroxisome proliferator-activated receptor gamma
(PPAR-γ) activation with TZDs leads to unbalanced bone
remodelling with bone resorption increasing and bone forma-
tion decreasing [27].
A limitation of our analysis is that inference based on
cumulative exposure does not exclude confounding by gly-
caemia. Although we do not have good coverage of HbA1c
in the first few years of follow-up, even if we had complete
HbA1c data simply adjusting for HbA1c would be incorrect
since it potentially determines exposure and is also altered
by exposure [28]. A much better test of whether HbA1c is
likely to be a relevant confounder here therefore is the
specificity of association; if HbA1c were a confounder then
we would expect to also see such confounding causing an
apparent relationship with other glucose-lowering drugs and
fractures risk, which is not the case.
It is vital to consider the importance of the elevated risk
of hip fracture compared with the possible elevated risk of
bladder cancer in users of pioglitazone, which has recently
led to a label change by the US Food and Drugs Adminis-
tration (FDA) and EMA. The FDA estimated that the risk
difference for bladder cancer associated with exposure to
pioglitazone for more than 12 months was 28 cases per
100,000 person-years of follow-up [29]. Five-year mortality
for bladder cancer is about 50% [30]. For comparison, an
approximate estimate of the absolute risk difference for hip
fracture in TZD users can be obtained from Figs 1 and 2 by
comparing the age-standardised rate at, say, 0–2 years ex-
posure with 2–4 years exposure. This risk difference is
approximately 1.4 per 1,000 person-years in women and
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0.7 per 1,000 person-years in men. Consistent with the
established literature [14, 15], we found high 90-day case-
fatality rates of 15% in TZD users, similar to rates in never-
users. Based on this case-fatality information we can thus
estimate that TZD use for 2 years or more will carry an
excess mortality of at least 21 per 100,000 woman-years
from hip fracture, compared with an estimated excess mor-
tality of about 14 per 100,000 person-years from bladder
cancer in those exposed to pioglitazone.
Thus, hip fracture should be considered at least as important
a potential adverse effect of pioglitazone exposure as bladder
cancer to be balanced against its efficacy in reducing HbA1c.
Of note the recent EMA risk–benefit assessment of pioglita-
zone carried out following the emergence of bladder cancer
data does not even mention fracture risk [31]. This suggests
that the importance of this adverse effect is not fully appreci-
ated and should be emphasised to clinicians and patients.
Current TZD drug labels state that ‘the risk of fracture should
be considered’ but emphasise that effects are on distal fracture
and mostly in women. These labels should be changed to
reflect the accumulated data on hip fracture and risk in men.
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Appendix
Inclusion and exclusion ICD-10 codes
Inclusion
S72.0 Fracture neck of femur not otherwise
specified
S72.1 Pertrochanteric fracture
S72.2 Subtrochanteric fracture
Exclusion
V01 to V99 Transport accidents
W11 to W17 Falls from one level to another or
external collisions other than fall
from stairs or steps
W20 to W49 Certain external causes of accidental
injury e.g. being struck by objects
X70, X72 to X75, X79 Certain acts of intentional self harm
likely to cause fracture
X91, X93 to X96, X99 Assault
Y00-Y04, Y08, Y09,Y22
to Y25, Y30 to Y32
Certain accidents of undetermined intent
Y35 to Y36 Injuries due to legal intervention and war
Y86 Sequelae of other accidents
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